Clinical trial · Observational
Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects
NCT01183832CI-TRIAL-00038842ORACLEScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is a description of the radiation effects on the healthy tissues in patients receiving Anastrozole, sequential or in association with radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Concomitant
- description
- In this group, anastrazole is concomitant to the radiotherapy
- label
- Sequential
- description
- In this group, anastrazole is sequential to the radiotherapy (start after the end of radiotherapy)
Primary outcomes (1)
- measure
- radiation side effects
- timeFrame
- 5 years after the end of radiotherapy
- description
- Describe, in real situation, the ionisant radiation effects on the healthy tissues in patients receiving anastrazole in association or sequential with radiotherapy
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Post-menopausal woman without superior age limit * No metastatic breast cancer, stade I-II, estrogen receptor positive or progesterone receptor positive, treated by conservative surgery or total mastectomy and requiring additive treatment by radiotherapy and hormonotherapy * The patients including in another clinical trial can be include in this observatory
References
Publications (0)
Data not yet available
No reference posted for this study.